Focal segmental glomerulosclerosis (FSGS) is a well-defined histologic pattern of injury characterized by sclerosis, hyalinosis, foam-cell infiltration, vacuolization of podocytes, and podocyte precursor proliferation between glomeruli tuft and Bowman’s capsule. It is “focal” in that only some glomeruli are affected and “segmental” where only a portion of the affected glomerulus is sclerosed.FSGS may be found either as primary or secondary forms. Primary FSGS sometimes has no identifiable cause or known etiology and linked to genetic mutations in podocyte-specific proteins, while secondary FSGS might include familial/genetic forms, virus-associated forms, drug-induced forms, and forms mediated by adaptive structural-functional response.

 

The clinical features of FSGS include peripheral edema, marked proteinuria, hypertension, hypoalbuminemia, hyperlipidemia, and progressive loss of renal function. The pathogenesis of FSGS is very complex, mostly podocyte injury and parietal epithelial cells lining Bowman’s capsule play a central role in the disease progression. FSGS is classified as collapsing, tip, cellular, perihilar, and not otherwise specified variants according to the location and character of the sclerotic lesion (Columbia Classification).

 

 

 

The report provides insights into: 

• All of the companies that are developing therapies for the treatment of Focal Segmental Glomerulosclerosis (FSGS) with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Focal Segmental Glomerulosclerosis (FSGS) treatment.
• Focal Segmental Glomerulosclerosis (FSGS) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Focal Segmental Glomerulosclerosis (FSGS) market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.  

Analytical Perspective

• In-depth Focal Segmental Glomerulosclerosis (FSGS) Commercial Assessment of products 

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

• Focal Segmental Glomerulosclerosis (FSGS) Clinical Assessment of products 

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Report Highlights:- 

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Focal Segmental Glomerulosclerosis (FSGS).    
• In the coming years, the Focal Segmental Glomerulosclerosis (FSGS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 
• The companies and academics that are working to assess challenges and seek opportunities that could influence Focal Segmental Glomerulosclerosis (FSGS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Focal Segmental Glomerulosclerosis (FSGS) treatment market. Several potential therapies for Focal Segmental Glomerulosclerosis (FSGS) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Focal Segmental Glomerulosclerosis (FSGS) market size in the coming years.  
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Focal Segmental Glomerulosclerosis (FSGS)) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

 

 Report Key facts:- 

1.  Age plays important role in the prevalence of FSGS. As per DelveInsight estimates, there were 4,306 cases of children with FSGS, while adults contribute 8,613 cases of FSGS in 2017 for Germany.

2. In 2017, there were 45,852 prevalent cases of FSGS in males and 34,731 cases in females and as per analyst assessments, the overall cases of FSGS in both the genders is subjected to increase in the coming years in 7MM.

 “According to DelveInsight’s analysis, Male cases of FSGS are more prominent in comparison to Female”

Key companies are working on FSGS are given below:-

1. Retrophin Pharma Co

2. Dimerix Pharma Co. 

3.Aurinia Pharmaceuticals.

Name of drugs covered that are given below:- 

1. Sparsentan
2. DMX-200
3. Voclosporin

Table of Contents

1. Report Introduction

2. Focal Segmental Glomerulosclerosis (FSGS) 

2.1. Overview

2.2. History 

2.3. Focal Segmental Glomerulosclerosis (FSGS) Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Focal Segmental Glomerulosclerosis (FSGS) Diagnosis 

2.6.1. Diagnostic Guidelines

3. Focal Segmental Glomerulosclerosis (FSGS) Current Treatment Patterns

3.1. Focal Segmental Glomerulosclerosis (FSGS) Treatment Guidelines

4. Focal Segmental Glomerulosclerosis (FSGS) – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Focal Segmental Glomerulosclerosis (FSGS) companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Focal Segmental Glomerulosclerosis (FSGS) Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Focal Segmental Glomerulosclerosis (FSGS) Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Focal Segmental Glomerulosclerosis (FSGS) Late Stage Products (Phase-III)

7. Focal Segmental Glomerulosclerosis (FSGS) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Focal Segmental Glomerulosclerosis (FSGS) Discontinued Products

13. Focal Segmental Glomerulosclerosis (FSGS) Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition 

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report? 

14. Focal Segmental Glomerulosclerosis (FSGS) Key Companies

15. Focal Segmental Glomerulosclerosis (FSGS) Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Focal Segmental Glomerulosclerosis (FSGS) Unmet Needs

18. Focal Segmental Glomerulosclerosis (FSGS) Future Perspectives

19. Focal Segmental Glomerulosclerosis (FSGS) Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation 

22. About Delveinsight

Related Reports:-

1. Focal Segmental Glomerulosclerosis (FSGS)- Market Insight, Epidemiology and Market Forecast -2030

2. Focal Segmental Glomerulosclerosis (FSGS) – Epidemiology Forecast to 2030